Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14313606 | 0.82 | ALDH1A1 (0.36) | CYP2C9CYP2C19KMT2AMEN1CYP3A4 | |
| SCHEMBL15236865 | 0.82 | ALDH1A1 (0.36) | CYP2C9CYP2C19KMT2AMEN1CYP3A4 | |
| SCHEMBL17893326 | 0.81 | NPSR1 (0.43) | NPSR1KMT2AMEN1CYP3A4POLB | |
| SCHEMBL15115661 | 0.80 | FFAR3 (0.43) | ALDH1A1SMN1; SMN2HSD11B1 | |
| SCHEMBL3198604 | 0.80 | KMT2A (0.38) | NPSR1CYP2C19KMT2AMEN1CYP3A4 | |
| SCHEMBL1928676 | 0.77 | — | — | |
| SCHEMBL11353255 | 0.76 | NPSR1 (0.39) | NPSR1KMT2AMEN1CYP3A4POLB | |
| SCHEMBL17893331 | 0.74 | FFAR3 (0.44) | NPSR1KMT2AMEN1CYP3A4POLB | |
| SCHEMBL17958 | 0.72 | NPSR1 (0.52) | NPSR1KMT2AMEN1CYP3A4LMNA | |
| SCHEMBL17893308 | 0.72 | FFAR3 (0.43) | NPSR1KMT2AMEN1CYP3A4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576546-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE BAHAMAS LTD (BS) | 2015-07-22 | — | — | EP | disclosed |
| US-9034875-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8580794-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130267514-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2013-10-10 | — | — | US | disclosed |
| EP-2576546-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011149492-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267514-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | NPSR1 4799/4885CYP2C9 4868/4885CYP2C19 4870/4885 |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | NPSR1 4799/4885CYP2C9 4868/4885CYP2C19 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.